Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 13/20 | 0.56 |
| ▸ | PTGDR | Q13258 | 6/20 | 0.56 |
| ▸ | NPY1R | P25929 | 1/20 | 0.43 |
| ▸ | NPY2R | P49146 | 1/20 | 0.43 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2287091 | 0.75 | AAK1 (0.47) | LMNANPSR1NPC1HPGDRAB9A | |
| SCHEMBL13262573 | 0.74 | PTGDR2 (0.59) | PTGDR2PTGDRNPY1RNPY2RPTGER2 | |
| SCHEMBL17316727 | 0.74 | PTGDR2 (0.51) | PTGDR2PTGDR | |
| SCHEMBL22208677 | 0.74 | TSHR (0.46) | LMNANPSR1NPC1HPGDRAB9A | |
| SCHEMBL4816613 | 0.74 | SMN1; SMN2 (0.42) | PTGDR2LMNANPC1HPGDRAB9A | |
| SCHEMBL941193 | 0.74 | GLA (0.42) | PTGDR2LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL6619470 | 0.73 | PTGDR2 (0.42) | PTGDR2PTGDRNPY1RNPY2RNPSR1 | |
| SCHEMBL6449169 | 0.73 | PTGDR2 (0.51) | PTGDR2PTGDRNPY1RNPY2RPTGER2 | |
| SCHEMBL2863698 | 0.72 | KMT2A (0.44) | PTGDR2NPY1RNPY2RLMNANPC1 | |
| SCHEMBL4882946 | 0.72 | PTGDR2 (1.00) | PTGDR2PTGDRPTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014767-A1 | Benzoxazole, benzothiazole, and benzimidazole derivatives for the treatment of cancer and other diseases | INCYTE CORPORATION | 2005-01-20 | — | — | US | disclosed |
| WO-2004066952-A2 | BENZOXAZOLE, BENZOTHIAZOLE, AND BENZIMIDAZOLE DERIVATIVES FOR THE TREATMENT OF CANCER AND OTHER DISEASES | INCYTE CORPORATION (US) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014767-A1 | Benzoxazole, benzothiazole, and benzimidazole derivatives for the treatment of cancer and other diseases | AR, CCNT1, BRD1 | PTGDR2 941/4885PTGDR 1117/4885NPY1R 919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.